Covid-19 Research

Review Article

Emerging Therapeutic Role of CDK Inhibitors in Targeting Cancer Stem Cells

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Review Article
Subject Medicine Group
OCLC 9382545806
Sadia Perveen, Hanfa Ashfaq#, Mehak Shahid, Ambreen Kanwal and Asima Tayyeb*
Issue: Volume2-Issue11
Pages: 1111-1116
Received: 2021-10-18
Accepted: 2021-11-12
Published: 2021-11-20

Abstract

Within a tumor, Cancer Stem Cells (CSCs) exists and own similar characteristics of a normal stem cell thus contributing towards aggressiveness of cancer by playing crucial role in tumor recurrence and metastasis capability. Various studies have been conducted to therapeutically target CSCs. One of the approaches include is to inhibit cell cycle progression in CSCs. Within last two decades cell cycle and role of various components in its regulation is firmly established. Cell cycle is regulated by Cyclin Dependent Kinases (CDK) bound to cyclin. CDK activity can be blocked by Cyclin-Dependent Kinase Inhibitors (CKIs) which can either bind cyclin/CDK complex or CDK alone and thus stops cell cycle. In this review various studies are discussed that have investigated the therapeutic role of CKIs in eradicating CSCs by inhibiting cell cycle. Overall, the analysis suggests that CKIs could be a potential therapeutic option in controlling CSCs populating in a tumor.

FullText HTML FullText PDF DOI: 10.37871/jbres1355 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Parveen S, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Perveen S, Ashfaq H, Shahid M, Kanwal A, Tayyeb A. Emerging Therapeutic Role of CDK Inhibitors in Targeting Cancer Stem Cells. J Biomed Res Environ Sci. 2021 Nov 20; 2(11): 1111-1116. doi: 10.37871/jbres1355, Article ID: JBRES1355, Available at: https://www.jelsciences.com/articles/jbres1355.pdf

Subject area(s)

Stem CellsTherapeutics

University/Institute

University of Punjab

References

  1. Clarke Mf, Hass At. Cancer stem cells. Reviews in Cell Biology and Molecular Medicine. 2006;1:24-30. doi: 10.1002/3527600906.mcb.200300130
  2. Koury J, Zhong L, Hao J. Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment. Stem Cells Int. 2017;2017:2925869. doi: 10.1155/2017/2925869. Epub 2017 Mar 5. PMID: 28356914; PMCID: PMC5357538.
  3. Bhattacharya R, Banerjee K, Mukherjee N, Sen M, et al. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer. Pathology-Research and Practice. 2017;213(3):177-182. doi: 10.1016/j.prp.2017.01.001
  4. Bonuccelli G, Peiris-Pages M, Ozsvari B, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. Oncotarget. 2017 Feb 7;8(6):9868-9884. doi: 10.18632/oncotarget.14196. PMID: 28039467; PMCID: PMC5354777.
  5. Wang KH, Kao AP, Lin TC, Chang CC, Kuo TC. Promotion of epithelial-mesenchymal transition and tumor growth by 17β-estradiol in an ER(+)/HER2(+) cell line derived from human breast epithelial stem cells. Biotechnol Appl Biochem. 2012 May-Jun;59(3):262-7. doi: 10.1002/bab.1022. PMID: 23586837.
  6. Han YK, Lee JH, Park GY, Chun SH, Han JY, Kim SD, Lee J, Lee CW, Yang K, Lee CG. A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. Biochem Biophys Res Commun. 2013 Jan 25;430(4):1329-33. doi: 10.1016/j.bbrc.2012.10.119. Epub 2012 Dec 19. PMID: 23261434.
  7. Li X, Wang H, Ding J, Nie S, Wang L, Zhang L, Ren S. Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. Eur J Pharmacol. 2019 Jan 5;842:146-156. doi: 10.1016/j.ejphar.2018.10.043. Epub 2018 Oct 30. PMID: 30389635.
  8. Kishino E, Ogata R, Saitoh W, Koike Y, Ohta Y, Kanomata N, Kurebayashi J. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells. Breast Cancer. 2020 May;27(3):415-425. doi: 10.1007/s12282-019-01035-5. Epub 2019 Dec 10. PMID: 31823286.
  9. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci. 2008 Jun;29(6):302-13. doi: 10.1016/j.tips.2008.03.003. Epub 2008 Apr 16. PMID: 18423896.
  10. Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015 Apr;31:16-27. doi: 10.1016/j.semcancer.2014.06.004. Epub 2014 Jun 20. PMID: 24956577.
  11. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997 Jul;3(7):730-7. doi: 10.1038/nm0797-730. PMID: 9212098.
  12. Weitensteiner SB, Liebl J, Krystof V, Havlíček L, Gucký T, Strnad M, Fürst R, Vollmar AM, Zahler S. Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS One. 2013;8(1):e54607. doi: 10.1371/journal.pone.0054607. Epub 2013 Jan 15. PMID: 23336010; PMCID: PMC3545992.
  13. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology. 2018;13(1):21-38. doi: 10.1007/s11523-017-0541
  14. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011 Oct;137(10):1409-18. doi: 10.1007/s00432-011-1039-4. Epub 2011 Aug 30. PMID: 21877198.
  15. Maclachlan Tk, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr. 1995;5(2):127-56. doi: 10.1615/critreveukargeneexpr.v5.i2.20. PMID: 8845581.
  16. Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su TC, Huang RH, Wen CK, Chen CY, Chen CJ, Yeh KT. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014 Dec 15;14:951. doi: 10.1186/1471-2407-14-951. PMID: 25511643; PMCID: PMC4302138.
  17. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 2009;11(1):R12. doi: 10.1186/bcr2231. Epub 2009 Feb 24. PMID: 19239702; PMCID: PMC2687717.
  18. Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W, Cheung TT. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018 Jun 13;8(14):3737-3750. doi: 10.7150/thno.25487. PMID: 30083256; PMCID: PMC6071527.
  19. Ying X, Che X, Wang J, Zou G, Yu Q, Zhang X. CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer. J Cancer. 2021 Feb 22;12(8):2206-2215. doi: 10.7150/jca.51139. PMID: 33758599; PMCID: PMC7974891.
  20. Sunada S, Saito H, Zhang D, Xu Z, Miki Y. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity. Biochem Biophys Res Commun. 2021 Apr 23;550:56-61. doi: 10.1016/j.bbrc.2021.02.117. Epub 2021 Mar 5. PMID: 33684621.
  21. Bury M, Le Calvé B, Lessard F, Dal Maso T, Saliba J, Michiels C, Ferbeyre G, Blank V. NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor. Cell Rep. 2019 Nov 5;29(6):1469-1481.e9. doi: 10.1016/j.celrep.2019.09.087. PMID: 31693889.
  22. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003 Mar;3(3):233-45. doi: 10.1016/s1535-6108(03)00053-9. PMID: 12676582.
  23. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. PMID: 21278435.
  24. Lim TG, Lee SY, Huang Z, Lim DY, Chen H, Jung SK, Bode AM, Lee KW, Dong Z. Curcumin suppresses proliferation of colon cancer cells by targeting CDK2. Cancer Prev Res (Phila). 2014 Apr;7(4):466-74. doi: 10.1158/1940-6207.CAPR-13-0387. Epub 2014 Feb 18. PMID: 24550143; PMCID: PMC3988585.
  25. Zhang Z, Huang A, Zhang A, Zhou C. HuR promotes breast cancer cell proliferation and survival via binding to CDK3 mRNA. Biomed Pharmacother. 2017 Jul;91:788-795. doi: 10.1016/j.biopha.2017.04.063. Epub 2017 May 10. PMID: 28501005.
  26. Zhang Y, Yang L, Ling C, Heng W. HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis. Biotechnol Lett. 2018 Apr;40(4):623-631. doi: 10.1007/s10529-018-2512-9. Epub 2018 Jan 17. PMID: 29344850.
  27. Dai M, Zhang C, Ali A, Hong X, Tian J, Lo C, Fils-Aimé N, Burgos SA, Ali S, Lebrun JJ. CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. Sci Rep. 2016 Oct 19;6:35383. doi: 10.1038/srep35383. PMID: 27759034; PMCID: PMC5069501.
  28. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan;16(1):103-19. doi: 10.1517/14728222.2011.645805. Epub 2012 Jan 12. PMID: 22239440; PMCID: PMC3457779.
  29. Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Epub 2016 Mar 8. PMID: 27017286.
  30. Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. 2018 Jul 9;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023. Epub 2018 May 3. PMID: 29731395; PMCID: PMC6039233.
  31. Shimura T, Noma N, Oikawa T, Ochiai Y, Kakuda S, Kuwahara Y, Takai Y, Takahashi A, Fukumoto M. Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis. 2012 Jun 4;1(6):e12. doi: 10.1038/oncsis.2012.12. PMID: 23552696; PMCID: PMC3412645.
  32. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010 Nov 15;70(22):9473-82. doi: 10.1158/0008-5472.CAN-10-2746. Epub 2010 Nov 9. PMID: 21062975.
  33. Chashoo G, Saxena A. Targetting Cdks in cancer:An overview and new insights.J Cancer Sci Ther. 2014;6(12):488-496. doi: 10.4172/1948-5956.1000313
  34. Mandl MM, Zhang S, Ulrich M, Schmoeckel E, Mayr D, Vollmar AM, Liebl J. Inhibition of Cdk5 induces cell death of tumor-initiating cells. Br J Cancer. 2017 Mar 28;116(7):912-922. doi: 10.1038/bjc.2017.39. Epub 2017 Feb 21. PMID: 28222068; PMCID: PMC5379151.
  35. Mukherjee S, Tucker-Burden C, Kaissi E, Newsam A, Duggireddy H, Chau M, Zhang C, Diwedi B, Rupji M, Seby S, Kowalski J, Kong J, Read R, Brat DJ. CDK5 Inhibition Resolves PKA/cAMP-Independent Activation of CREB1 Signaling in Glioma Stem Cells. Cell Rep. 2018 May 8;23(6):1651-1664. doi: 10.1016/j.celrep.2018.04.016. PMID: 29742423; PMCID: PMC5987254.
  36. Du Q, Guo X, Wang M, Li Y, Sun X, Li Q. The application and prospect of CDK4/6 inhibitors in malignant solid tumors. J Hematol Oncol. 2020 May 1;13(1):41. doi: 10.1186/s13045-020-00880-8. PMID: 32357912; PMCID: PMC7195725.
  37. Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8. PMID: 32385714; PMCID: PMC7497306.
  38. Coates Da, Montero C, Patel Bkr, Remick Dm, et al. Compounds useful for inhibiting cdk7. 2019.
  39. Xi M, Chen T, Wu C, Gao X, Wu Y, Luo X, Du K, Yu L, Cai T, Shen R, Sun H. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Eur J Med Chem. 2019 Feb 15;164:77-91. doi: 10.1016/j.ejmech.2018.11.076. Epub 2018 Dec 21. PMID: 30594029.
  40. Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. PMID: 30647871; PMCID: PMC6324664.
  41. Fan X. γ-Secretase inhibitor-resistant glioblastoma stem cells require RBPJ to propagate. J Clin Invest. 2016 Jul 1;126(7):2415-8. doi: 10.1172/JCI88619. Epub 2016 Jun 20. PMID: 27322058; PMCID: PMC4922718.
  42. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Nov 1;181:111535. doi: 10.1016/j.ejmech.2019.07.038. Epub 2019 Jul 25. PMID: 31376566.
  43. Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 2014 Sep;45(3):1193-9. doi: 10.3892/ijo.2014.2523. Epub 2014 Jun 25. PMID: 24970653; PMCID: PMC4121417.
  44. Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. Clin Cancer Res. 2019 Feb 1;25(3):921-927. doi: 10.1158/1078-0432.CCR-18-1967. Epub 2018 Oct 4. PMID: 30287548; PMCID: PMC6359975.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership